AbbVie to Acquire Apogee Therapeutics for $10.9 Billion All-Cash
AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash, valuing the clinical-stage immunology biotech at $10.9 billion. The all-cash transaction adds Apogee's portfolio of treatments for inflammatory and immunological diseases to AbbVie's pipeline.
AbbVie (ABBV) agreed to acquire Apogee Therapeutics (APGE) in an all-cash transaction valued at $135.11 per share, or $10.9 billion in total equity value. The deal adds Apogee's portfolio of clinical-stage treatments for inflammatory and immunological diseases to AbbVie's pipeline.
Apogee shareholders will receive $135.11 per share in cash. The announcement sent Apogee shares up 52 percent, reflecting the premium to the prior trading price. AbbVie is acquiring the entire company; no named executives or specific counterparties were disclosed in the available materials.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.